ATE286974T1 - Therapeutische domänen des von willebrand-faktor - Google Patents

Therapeutische domänen des von willebrand-faktor

Info

Publication number
ATE286974T1
ATE286974T1 AT93907272T AT93907272T ATE286974T1 AT E286974 T1 ATE286974 T1 AT E286974T1 AT 93907272 T AT93907272 T AT 93907272T AT 93907272 T AT93907272 T AT 93907272T AT E286974 T1 ATE286974 T1 AT E286974T1
Authority
AT
Austria
Prior art keywords
acid sequence
amino acid
von willebrand
willebrand factor
terminus
Prior art date
Application number
AT93907272T
Other languages
English (en)
Inventor
Zaverio M Ruggeri
Jerry L Ware
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE286974T1 publication Critical patent/ATE286974T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT93907272T 1992-02-26 1993-02-23 Therapeutische domänen des von willebrand-faktor ATE286974T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/841,591 US5900476A (en) 1986-05-30 1992-02-26 Therapeutic domains of van Willebrand factor
PCT/US1993/002034 WO1993016709A1 (en) 1992-02-26 1993-02-23 Therapeutic domains of von willebrand factor

Publications (1)

Publication Number Publication Date
ATE286974T1 true ATE286974T1 (de) 2005-01-15

Family

ID=25285252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93907272T ATE286974T1 (de) 1992-02-26 1993-02-23 Therapeutische domänen des von willebrand-faktor

Country Status (11)

Country Link
US (1) US5900476A (de)
EP (1) EP0627923B1 (de)
JP (1) JP3805358B2 (de)
AT (1) ATE286974T1 (de)
AU (1) AU3793493A (de)
CA (1) CA2130900C (de)
DE (1) DE69333738T2 (de)
ES (1) ES2235153T3 (de)
MX (1) MX9301111A (de)
SG (1) SG48173A1 (de)
WO (1) WO1993016709A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
WO2000024781A1 (en) * 1998-10-23 2000-05-04 The Brigham And Women's Hospital, Inc. Conformation-specific anti-von willebrand factor antibodies
AU2002220275A1 (en) * 2000-12-08 2002-06-18 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
GB0031448D0 (en) * 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
JP2008512098A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US20110034396A1 (en) * 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
US7691839B2 (en) * 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US20080015145A1 (en) 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
US20080160024A1 (en) * 2006-12-07 2008-07-03 Board Of Trustees Of The University Of Arkansas Inhibition of cancer metastasis
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
EP2244814B1 (de) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Formulierungen von rekombinantem vwf
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
NZ592704A (en) 2008-10-21 2013-02-22 Baxter Int Lyophilized recombinant von willebrand factor (rVWF) formulation comprising buffering agents, amino acids, stabilising agents and surfactants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
EP0255206B1 (de) * 1986-05-30 1995-03-22 The Scripps Research Institute Peptide, die die Bindung des Von-Willebrand-Faktors inhibieren
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
MX9203763A (es) * 1991-06-28 1993-08-01 Rhone Poulenc Rorer Int Polipeptidos terapeuticos a base del factor de von willebrand
WO1993011778A1 (en) * 1991-12-12 1993-06-24 The Scripps Research Institute Bifunctional antithrombotic molecules and antithrombotic polypeptides
FR2686901A1 (fr) * 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
AU3793493A (en) 1993-09-13
SG48173A1 (en) 1998-04-17
WO1993016709A1 (en) 1993-09-02
DE69333738D1 (de) 2005-02-17
ES2235153T3 (es) 2005-07-01
EP0627923A1 (de) 1994-12-14
CA2130900A1 (en) 1993-08-27
US5900476A (en) 1999-05-04
DE69333738T2 (de) 2005-12-01
EP0627923A4 (de) 1996-01-17
JPH07507270A (ja) 1995-08-10
CA2130900C (en) 2009-04-14
MX9301111A (es) 1994-08-31
EP0627923B1 (de) 2005-01-12
JP3805358B2 (ja) 2006-08-02

Similar Documents

Publication Publication Date Title
ATE286974T1 (de) Therapeutische domänen des von willebrand-faktor
DK0672138T3 (da) Kimære prokoagulante proteiner
DK0662827T4 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
DE69533544D1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
ES2059354T5 (es) Nuevo polipeptido.
DE68929430T2 (de) Fibronektin bindendes Protein
ES8801036A1 (es) Un metodo para detectar la presencia de un inhibidor de anticuerpos de factor viii humano en una muestra
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
DE69607034T2 (de) Pcna bindende substanz
DE69837265D1 (de) Polypeptide zur regenerierung des nervensystems
EP0367641A3 (en) Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines
ATE351909T1 (de) Neue peptidfragmente zur reinigung von proteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0627923

Country of ref document: EP